NASDAQ:ARVN

Arvinas Competitors

$64.69
+1.69 (+2.68 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$61.99
Now: $64.69
$65.35
50-Day Range
$58.19
MA: $68.47
$78.30
52-Week Range
$19.68
Now: $64.69
$92.77
Volume521,100 shs
Average Volume487,086 shs
Market Capitalization$3.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.14

Competitors

Arvinas (NASDAQ:ARVN) Vs. GRFS, TEVA, RDY, BHC, JAZZ, and MRVI

Should you be buying ARVN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Arvinas, including Grifols (GRFS), Teva Pharmaceutical Industries (TEVA), Dr. Reddy's Laboratories (RDY), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), and Maravai LifeSciences (MRVI).

Arvinas (NASDAQ:ARVN) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares Arvinas and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arvinas-403.77%-46.99%-35.34%
Grifols12.79%10.65%4.79%

Insider & Institutional Ownership

75.7% of Arvinas shares are owned by institutional investors. Comparatively, 15.2% of Grifols shares are owned by institutional investors. 11.0% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Arvinas has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Arvinas and Grifols, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arvinas00903.00
Grifols02502.71

Arvinas presently has a consensus price target of $106.4545, suggesting a potential upside of 64.56%. Given Arvinas' stronger consensus rating and higher probable upside, equities research analysts clearly believe Arvinas is more favorable than Grifols.

Valuation & Earnings

This table compares Arvinas and Grifols' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$42.98 million73.56$-70,290,000.00($2.13)-30.37
Grifols$5.71 billion2.16$700.16 million$1.1715.37

Grifols has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Arvinas (NASDAQ:ARVN) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Valuation & Earnings

This table compares Arvinas and Teva Pharmaceutical Industries' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arvinas$42.98 million73.56$-70,290,000.00($2.13)-30.37
Teva Pharmaceutical Industries$16.89 billion0.70$-998,000,000.00$2.314.65

Arvinas has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Arvinas is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Arvinas and Teva Pharmaceutical Industries, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arvinas00903.00
Teva Pharmaceutical Industries18402.23

Arvinas presently has a consensus price target of $106.4545, suggesting a potential upside of 64.56%. Teva Pharmaceutical Industries has a consensus price target of $12.2222, suggesting a potential upside of 13.70%. Given Arvinas' stronger consensus rating and higher probable upside, equities research analysts clearly believe Arvinas is more favorable than Teva Pharmaceutical Industries.

Volatility & Risk

Arvinas has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.

Profitability

This table compares Arvinas and Teva Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arvinas-403.77%-46.99%-35.34%
Teva Pharmaceutical Industries-24.17%19.32%4.89%

Insider & Institutional Ownership

75.7% of Arvinas shares are owned by institutional investors. Comparatively, 51.2% of Teva Pharmaceutical Industries shares are owned by institutional investors. 11.0% of Arvinas shares are owned by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Arvinas beats Teva Pharmaceutical Industries on 8 of the 14 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Earnings and Valuation

This table compares Dr. Reddy's Laboratories and Arvinas' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$2.32 billion4.67$259 million$2.7923.30
Arvinas$42.98 million73.56$-70,290,000.00($2.13)-30.37

Dr. Reddy's Laboratories has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Dr. Reddy's Laboratories and Arvinas, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dr. Reddy's Laboratories00403.00
Arvinas00903.00

Dr. Reddy's Laboratories presently has a consensus price target of $70.00, suggesting a potential upside of 7.68%. Arvinas has a consensus price target of $106.4545, suggesting a potential upside of 64.56%. Given Arvinas' higher probable upside, analysts plainly believe Arvinas is more favorable than Dr. Reddy's Laboratories.

Volatility & Risk

Dr. Reddy's Laboratories has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500.

Profitability

This table compares Dr. Reddy's Laboratories and Arvinas' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dr. Reddy's Laboratories8.23%16.33%10.79%
Arvinas-403.77%-46.99%-35.34%

Institutional & Insider Ownership

12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 75.7% of Arvinas shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 11.0% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Dr. Reddy's Laboratories beats Arvinas on 7 of the 13 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Arvinas (NASDAQ:ARVN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Profitability

This table compares Bausch Health Companies and Arvinas' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bausch Health Companies-23.92%173.20%4.21%
Arvinas-403.77%-46.99%-35.34%

Volatility & Risk

Bausch Health Companies has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500.

Earnings and Valuation

This table compares Bausch Health Companies and Arvinas' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health Companies$8.60 billion1.24$-1,788,000,000.00$4.436.78
Arvinas$42.98 million73.56$-70,290,000.00($2.13)-30.37

Arvinas has lower revenue, but higher earnings than Bausch Health Companies. Arvinas is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. Comparatively, 75.7% of Arvinas shares are held by institutional investors. 12.1% of Bausch Health Companies shares are held by company insiders. Comparatively, 11.0% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Bausch Health Companies and Arvinas, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bausch Health Companies14702.50
Arvinas00903.00

Bausch Health Companies presently has a consensus price target of $32.5833, suggesting a potential upside of 8.50%. Arvinas has a consensus price target of $106.4545, suggesting a potential upside of 64.56%. Given Arvinas' stronger consensus rating and higher probable upside, analysts plainly believe Arvinas is more favorable than Bausch Health Companies.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Arvinas (NASDAQ:ARVN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Profitability

This table compares Jazz Pharmaceuticals and Arvinas' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Jazz Pharmaceuticals7.86%20.16%10.85%
Arvinas-403.77%-46.99%-35.34%

Risk & Volatility

Jazz Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Arvinas has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500.

Valuation & Earnings

This table compares Jazz Pharmaceuticals and Arvinas' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$2.16 billion4.40$523.37 million$14.6011.57
Arvinas$42.98 million73.56$-70,290,000.00($2.13)-30.37

Jazz Pharmaceuticals has higher revenue and earnings than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

95.7% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 75.7% of Arvinas shares are held by institutional investors. 4.6% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 11.0% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Jazz Pharmaceuticals and Arvinas, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Jazz Pharmaceuticals111602.83
Arvinas00903.00

Jazz Pharmaceuticals presently has a consensus target price of $186.7778, suggesting a potential upside of 10.58%. Arvinas has a consensus target price of $106.4545, suggesting a potential upside of 64.56%. Given Arvinas' stronger consensus rating and higher possible upside, analysts plainly believe Arvinas is more favorable than Jazz Pharmaceuticals.

Summary

Jazz Pharmaceuticals beats Arvinas on 9 of the 14 factors compared between the two stocks.

Maravai LifeSciences (NASDAQ:MRVI) and Arvinas (NASDAQ:ARVN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Profitability

This table compares Maravai LifeSciences and Arvinas' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Maravai LifeSciencesN/AN/AN/A
Arvinas-403.77%-46.99%-35.34%

Valuation & Earnings

This table compares Maravai LifeSciences and Arvinas' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciencesN/AN/AN/AN/AN/A
Arvinas$42.98 million73.56$-70,290,000.00($2.13)-30.37

Maravai LifeSciences has higher earnings, but lower revenue than Arvinas.

Insider and Institutional Ownership

75.7% of Arvinas shares are held by institutional investors. 11.0% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Maravai LifeSciences and Arvinas, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Maravai LifeSciences001003.00
Arvinas00903.00

Maravai LifeSciences presently has a consensus target price of $38.1250, suggesting a potential upside of 3.94%. Arvinas has a consensus target price of $106.4545, suggesting a potential upside of 64.56%. Given Arvinas' higher possible upside, analysts plainly believe Arvinas is more favorable than Maravai LifeSciences.


Arvinas Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Grifols logo
GRFS
Grifols
1.3$17.98+1.6%$12.36 billion$5.71 billion16.05Upcoming Earnings
Gap Up
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.75+0.7%$11.74 billion$16.89 billion-2.92Decrease in Short Interest
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$65.01+1.4%$10.81 billion$2.32 billion53.73
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$30.03+0.9%$10.68 billion$8.60 billion-5.51
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$168.90+0.3%$9.51 billion$2.16 billion53.28
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.68+0.1%$9.45 billionN/A0.00Increase in Short Interest
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.73+1.0%$9.07 billion$1.45 billion19.27
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$55.12+0.3%$8.21 billion$40.56 million-16.16
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$158.19+3.7%$8.01 billion$3.34 million-20.54Unusual Options Activity
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$108.72+0.8%$7.28 billion$103.71 million-24.77
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.65+0.5%$7.02 billion$87.99 million-80.54
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.90+0.0%$6.86 billion$311.33 million-127.27Increase in Short Interest
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$121.95+1.8%$6.55 billion$14.98 million-14.85
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$44.78+2.3%$6.30 billion$150,000.00-21.12High Trading Volume
Gap Down
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$40.78+0.6%$5.74 billion$1.12 billion84.96Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$71.80+1.2%$5.70 billion$380.83 million-9.18Analyst Report
Perrigo logo
PRGO
Perrigo
2.3$41.62+1.1%$5.56 billion$4.84 billion-693.55
Allakos logo
ALLK
Allakos
1.7$104.50+3.5%$5.55 billionN/A-38.14
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.20+0.8%$5.52 billion$66.51 million17.56
Schrödinger logo
SDGR
Schrödinger
1.3$77.90+0.6%$5.45 billion$85.54 million0.00
Galapagos logo
GLPG
Galapagos
1.3$79.15+0.3%$5.19 billion$1.00 billion-11.99
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.40+1.9%$4.62 billionN/A-6.06Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.64+1.2%$4.36 billion$6.87 million-7.21
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.25+0.4%$4.26 billion$204.89 million-36.56
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.64+4.1%$4.16 billion$1.11 billion24.96
I-Mab logo
IMAB
I-Mab
1.2$57.00+0.2%$4.10 billion$4.31 million-1.97Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90+3.2%$3.98 billion$806.43 million-9.33
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$54.69+0.6%$3.82 billion$117.91 million-11.09
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$44.94+2.4%$3.72 billionN/A0.00Increase in Short Interest
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.57+1.8%$3.66 billionN/A-6.14Analyst Report
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.03+5.8%$3.58 billionN/A-20.81
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.00+1.9%$3.46 billion$114.62 million-7.66Insider Selling
LEGN
Legend Biotech
1.2$26.00+0.8%$3.46 billion$64.39 million0.00Decrease in Short Interest
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.59+0.8%$3.42 billion$306.98 million-6.95
Insmed logo
INSM
Insmed
1.2$33.07+1.7%$3.42 billion$136.47 million-12.72
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.15+0.2%$3.38 billion$339.08 million-12.30High Trading Volume
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$90.87+1.5%$3.29 billion$26.52 million-8.01
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.54+1.3%$3.25 billion$36.13 million-69.46
Alkermes logo
ALKS
Alkermes
1.2$19.87+0.5%$3.16 billion$1.17 billion-43.19Insider Selling
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$112.60+4.2%$3.04 billionN/A-56.02
MorphoSys logo
MOR
MorphoSys
0.3$22.65+2.3%$2.98 billion$80.43 million107.86
OPKO Health logo
OPK
OPKO Health
1.9$4.34+0.5%$2.91 billion$901.90 million-24.11
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.64+1.6%$2.89 billion$644.77 million-10.79
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.1$63.07+5.2%$2.77 billion$421.03 million22.21High Trading Volume
Gap Up
Organogenesis logo
ORGO
Organogenesis
1.0$21.46+5.3%$2.75 billion$260.98 million-357.67Analyst Downgrade
Gap Down
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.00+0.5%$2.71 billion$25 million-9.40
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.39+0.9%$2.68 billionN/A-23.84
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.76+0.8%$2.67 billion$306.49 million25.57
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.94+3.9%$2.63 billion$182.24 million-8.64
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$40.81+1.3%$2.54 billion$2.11 million-8.83Analyst Revision
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.